

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

### Service Category

- |  |   |
|--|---|
| <input type="checkbox"/> Anesthesia                          | <input type="checkbox"/> Medicine Services and Procedures   |
| <input type="checkbox"/> Surgery                             | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures                | <input type="checkbox"/> DME/Prosthetics or Supplies        |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Part B Drugs            |

### Service Description

This document addresses the use of **Pemetrexed agents, including Alimta<sup>®</sup> (pemetrexed disodium), Pemfexy<sup>®</sup> (pemetrexed), Pemrydi RTU<sup>®</sup> (pemetrexed), and Axtle<sup>®</sup> (pemetrexed dipotassium)**. Pemetrexed is a folate analog metabolic inhibitor approved by the Food and Drug Administration (FDA) for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery and non-squamous cell lung cancer (NSCLC).

### Background Information

Pemetrexed is a folate analog with a pyrimidine base structure, and it exerts its anti-tumor effects by suppressing both DNA synthesis and folate metabolism through inhibition of multiple target enzymes. What sets pemetrexed apart is its ability to inhibit several enzymes simultaneously, a feature that distinguishes it from other drugs like methotrexate, which primarily targets dihydrofolate reductase, and 5-fluorouracil and raltitrexed, which mainly focus on thymidine synthetase. They work by inhibiting folate dependent metabolic processes which disrupts cell replication. Pemrydi is a ready to use presentation of pemetrexed for injection.

This multifaceted enzyme inhibition characteristic makes pemetrexed a potentially valuable option for treating cancers that have developed resistance to 5-fluorouracil, methotrexate, or raltitrexed. Pemetrexed functions as a "multitargeted" antifolate compound by disrupting two crucial pathways within folate metabolism: purine synthesis through inhibition of thymidylate synthase (TS) and dihydrofolate reductase (DHFR), as well as pyrimidine synthesis through the inhibition of glucinamide ribonucleotide formyl transferase (GARFT) and aminoimidazole carboxamide formyl transferase (AiCARFT), all of which are key enzymes in the folate metabolic pathway.

The FDA approved indications for Alimta, Pemfexy, Pemrydi, and Axtle include non-squamous (NSCLC) and malignant pleural mesothelioma.

### Non-Small Lung Cancer

- In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations (Alimta only\*).
- In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic,

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pefexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
--	---	--	--	---

non-squamous (NSCLC).

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta®, Axtle®, Pefexy®, Pemrydi®)	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
--	---	--	--	---

- As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- As a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.

### Malignant Pleural Mesothelioma

- In initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

The FDA states neither Alimta, Pefexy, Axtle, nor Pemrydi are indicated for the treatment of patients with squamous cell, non-small cell lung cancer.

The National Comprehensive Cancer Network (NCCN) provides additional recommendations with a category 2A level of evidence for the use of pemetrexed in cervical cancer, central nervous system lymphomas, ovarian cancer and thymomas and thymic carcinomas, and additional uses in NSCLC.

The NCCN panel includes category 1 recommendations for nonsquamous NSCLC continuation maintenance therapy for use of pembrolizumab in combination with pemetrexed if given first-line as part of pembrolizumab/carboplatin/pemetrexed or pembrolizumab/cisplatin/pemetrexed regimen. The NCCN panel also gives a category 1 and 2A recommendation for use of pemetrexed in combination with platinum-based therapy as adjuvant or neoadjuvant therapy in NSCLC (Kenmotsu 2020, Kreuter 2013, Zhang 2014).

The NCCN panel also gives a category 1 recommendation for use of pemetrexed in malignant mesothelioma as single agent, subsequent therapy.

The NCCN panel recommends that individuals with NSCLC be tested for actionable molecular markers, such as EGFR, ALK, ROS1, BRAF, NTRK, MET and RET mutations, before initiating first line therapy to help guide treatment. If there is insufficient tissue to allow testing for all of these markers, repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.

The NCCN panel does not differentiate between Alimta and Pefexy for any indication, including the use in NSCLC in combination with pembrolizumab and platinum therapy for initial treatment. Pemrydi is not yet addressed by NCCN.

### Definitions and Measures

- Chemotherapy: Medical treatment of a disease, particularly cancer, with drugs or other chemicals.
- ECOG or Eastern Cooperative Oncology Group Performance Status: A scale and criteria used by doctors and researchers to assess how an individual's disease is progressing, assess how the disease affects the

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pefexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
--	---	--	--	---

daily living abilities of the individual, and determine appropriate treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:

- o 0 = Fully active, able to carry on all pre-disease performance without restriction
  - o 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work
  - o 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
  - o 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
  - o 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
  - o 5 = Dead
- Immune checkpoint inhibitor: A type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include programmed death (PD)-1, PD-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated antigen (CTLA)-4/B7-1/B7-2.
  - Line of Therapy:
    - o First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
    - o Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
    - o Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.
  - Maintenance therapy: Designed to maintain a condition to prevent a relapse.
  - Metastasis: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.
  - Non-small cell lung cancer: A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.
  - Programmed death (PD)-1 proteins: PD-1 proteins are found on T-cells and attach to PD ligands (PD-L1) found on normal (and cancer) cells (see immune checkpoint inhibitor above). Normally, this process keeps T-cells from attacking other cells in the body. However, this can also prevent T-cells from attacking cancer cells in the body. Examples of FDA approved anti-PD-1 agents include Keytruda (pembrolizumab), Opdivo (nivolumab), and Libtayo (cemiplimab).
  - Programmed death ligand (PD-L)-1: The ligands found on normal (and cancer) cells to which the PD-1

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pefexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
--	---	--	--	---

proteins attach (see immune checkpoint inhibitor above). Cancer cells can have large amounts of PD-L1 on their surface, which helps them to avoid immune attacks. Examples of FDA approved anti-PD-L1 agents include Bavencio (avelumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab).

- Refractory Disease: Illness or disease that does not respond to treatment.

### Approved Indications

Pemetrexed agents (Alimta, Pefexy, Axtle, and Pemrydi) are approved by the FDA for the following indications:

- In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).
- As a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- As a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.
- In combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

*Limitation of use:* It's important to note that pemetrexed is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.

### Other Uses

- See background section above

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

### Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS	Description
J9304	Injection, pemetrexed, 10 mg [Pemfexy]
J9305	Injection, pemetrexed, NOS, 10 mg [Alimta]
J9324	Injection, pemetrexed (Pemrydi rtu), 10 mg
J9314	Injection, pemetrexed (Teva), not therapeutically equivalent to J9305, 10 mg
J9322	Injection, pemetrexed (BluePoint), not therapeutically equivalent to J9305, 10 mg
J9323	Injection, pemetrexed ditromethamine, 10 mg
J9292	Injection, pemetrexed dipotassium, 10 mg [Axtle]
J9294	Injection, pemetrexed (Hospira), not therapeutically equivalent to J9305, 10 mg
J9296	Injection, pemetrexed (Accord), not therapeutically equivalent to J9305, 10 mg
J9297	Injection, pemetrexed (Sandoz), not therapeutically equivalent to J9305, 10 mg
J9999	Not otherwise classified, antineoplastic drugs [Axtle]
C9399	Unclassified drugs or biologicals [Axtle]

ICD-10	Description
C00.0-C06.9	Malignant neoplasm of lip, tongue, and oral cavity
C09.0-C10.9	Malignant neoplasm of tonsil, oropharynx
C12-C14.8	Malignant neoplasm of pyriform sinus, hypopharynx, other and ill-defined sites in the lip, oral cavity and pharynx
C31.0-C32.9	Malignant neoplasm of accessory sinuses, larynx
C33	Malignant neoplasm of trachea
C34.00-C34.92	Malignant neoplasm of bronchus and lung
C37	Malignant neoplasm of thymus
C38.0-C38.8	Malignant neoplasm of heart, mediastinum and pleura
C38.4	Malignant neoplasm of pleura
C45.0-C45.9	Mesothelioma
C48.0-C48.8	Malignant neoplasm of retroperitoneum and peritoneum
C52	Malignant neoplasm of vagina

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta®, Axtle®, Pemfexy®, Pemrydi®)	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

C53.0-C53.9	Malignant neoplasm of cervix uteri
C56.1-C56.9	Malignant neoplasm of ovary
C57.00-C57.9	Malignant neoplasm of other and unspecified female genital organs
C76.0	Malignant neoplasm of head, face and neck
C79.32	Secondary malignant neoplasm of cerebral meninges
C83.390	Primary central nervous system lymphoma
D15.0	Benign neoplasm of thymus
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

### Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

#### *Pemetrexed (Alimta®, Axtle®, Pemfexy®, and Pemrydi®)*

**A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

- i. Individual has a diagnosis of malignant mesothelioma; **AND**
  - A. Individual is using in combination with cisplatin or carboplatin (Label, NCCN 2A); **OR**
  - B. Individual is using as a first-line therapy in combination with platinum-based chemotherapy AND bevacizumab (or bevacizumab biosimilar) (Label, NCCN 1); **AND**
    - 1. Individual has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; **AND**
    - 2. Individual does not have a history of hemoptysis or thrombosis; **AND**
    - 3. Disease presentation is unresectable;
  - OR**
  - C. Individual is using as a first-line therapy in combination with platinum-based chemotherapy and pembrolizumab (NCCN 1); **OR**
  - D. Individual is using as single agent for subsequent therapy (NCCN 1); **AND**
    - 1. Pemetrexed was not administered as first-line; **OR**
    - 2. Pemetrexed was used as first-line with good sustained response;

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

- E. Individual is using as single agent for first line systemic therapy (NCCN 2A);
- OR**
- ii. Individual has a diagnosis of recurrent, locally advanced, or metastatic non-squamous, non-small cell lung cancer (NSCLC); **AND**
- A. Individual is using as a single agent after prior chemotherapy; **OR**
  - B. Individual is using in combination with platinum based chemotherapy with or without bevacizumab (or bevacizumab biosimilar) (NCCN 2A); **OR**
  - C. Individual is using as a single agent for maintenance therapy; **OR**
  - D. Individual is using in combination with pembrolizumab (Keytruda) and platinum chemotherapy for initial treatment and without presence of actionable molecular markers (Label, NCCN 2A); **OR**
  - E. Individual is using as continuous maintenance therapy until disease progression, if given first-line as part of Keytruda (pembrolizumab)/platinum chemotherapy/and pemetrexed regimen (NCCN 1); **OR**
  - F. Individual is using in combination with cemiplimab and platinum chemotherapy; **OR**
  - G. Individual is using in combination with tremelimumab, durvalumab, and platinum chemotherapy; **OR**
  - H. Individual is using in combination with bevacizumab as continuous maintenance therapy, if given first-line as part of bevacizumab/ platinum/and pemetrexed regimen (NCCN 2A); **OR**
  - I. Individual is using in combination with cemiplimab as continuous maintenance therapy, if given first-line as part of cemiplimab/ platinum/and pemetrexed regimen (NCCN 2A); **OR**
  - J. Individual is using in combination with durvalumab as continuous maintenance therapy if given first-line as part of tremelimumab/durvalumab/platinum/and pemetrexed regimen (NCCN 2A); **OR**
  - K. Individual is using as first-line therapy in combination with nivolumab, ipilimumab, and platinum-based chemotherapy and without presence of actionable molecular markers (NCCN 2A); **OR**
  - L. Individual is using as adjuvant or neoadjuvant therapy in combination with platinum-based chemotherapy;
  - M. Individual is using in combination with Rybrevant (amivantamab-vmjw) and carboplatin (NCCN 1); **OR**
  - N. Individual is using as first-line therapy for EGFR exon 19 deletion or exon 21 L858R recurrent, advanced, or metastatic disease in combination with osimertinib and platinum-based chemotherapy (NCCN 1, 2A);

## Utilization Management and Clinical Medical Policy

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	MP-RX-FP-05-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	11/30/2023	03/24/2026
			Last Review Date:	Frequently Revision:
			03/24/2026	Annual

**OR**

- iii. Individual has a diagnosis of for EGFR mutation positive non-small cell lung cancer with leptomeningeal metastases; **AND**
- iv. Pemetrexed is being administered intrathecally;

**OR**

- v. Individual has a diagnosis of non-nasopharyngeal head and neck cancer (NCCN 2A);

**OR**

- vi. Individual is using as a single-agent therapy; **AND**
- vii. Individual has one of the following (NCCN 2A):
  - A. Individual has a diagnosis for persistent or recurrent ovarian cancer; **OR**
  - B. Individual has a diagnosis for thymic cancer and thymomas; **OR**
  - C. Individual is using pemetrexed as second-line or subsequent therapy for cervical cancer; **OR**
  - D. Individual has a diagnosis for primary central nervous system lymphoma; **OR**
  - E. Individual is using pemetrexed as second-line or subsequent therapy for vaginal cancer.

### B. Criteria For Continuation of Therapy

- i. MMM considers continuation of Pemetrexed (Alimta<sup>®</sup>, Axtle<sup>®</sup>, Pemfexy<sup>®</sup>, Pemrydi<sup>®</sup>) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when there is no evidence of unacceptable toxicity or disease progression while on the current regimen, and the maximum duration of treatment has not been exceeded. The following information should be submitted for reauthorization:
  - A. A current oncology note documenting the patient’s response to treatment showing no progression of disease.
  - B. Current imaging studies and other objective measures, as appropriate, showing no progression of disease when compared with previous results.
- ii. Duration of treatment:
  - A. When used for initial treatment of locally advanced or metastatic non-squamous NSCLC, in combination with cisplatin: Up to 6 cycles (21-days each cycle).
  - B. For all other diagnosis: Until disease progression or unacceptable toxicity.

### C. Authorization Duration

- i. Initial Approval Duration: Up to 6 months
- ii. Reauthorization Approval Duration: Up to 6 months

### D. Conditions Not Covered

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. Individual has a diagnosis of squamous cell non-small cell lung cancer; **OR**
- ii. When the above criteria are not met and for all other indications.

### Limits or Restrictions

#### A. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Pemetrexed (Alimta <sup>®</sup> , Pemfexy <sup>®</sup> , Axtle <sup>®</sup> , Pemrydi <sup>®</sup> )	Recommended Dosing Schedule	Recommended Treatment Duration
Initial treatment of locally advanced or metastatic non-squamous NSCLC, in combination with Pembrolizumab and a platinum, in patients with CrCl $\geq$ 45 mL/min	<ul style="list-style-type: none"> <li>500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle.</li> <li>Following platinum-based therapy, may continue pemetrexed (500 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle), as a single agent or with pembrolizumab, as maintenance therapy until disease progression or unacceptable toxicity.</li> </ul>	For up to 4 cycles or until disease progression or unacceptable toxicity.
Initial treatment of locally advanced or metastatic non-squamous NSCLC, in combination with cisplatin, in patients with CrCl $\geq$ 45 mL/min	<ul style="list-style-type: none"> <li>500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle</li> </ul>	For up to 6 cycles or until disease progression or unacceptable toxicity.
Maintenance treatment of locally advanced or metastatic NSCLC in patients with CrCl $\geq$ 45 mL/min	<ul style="list-style-type: none"> <li>After 4 cycles of initial platinum-based therapy: 500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle (as a single agent).</li> </ul>	Until Disease Progression or Unacceptable Toxicity.

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pefexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
--	---	--	--	---

Second-line treatment of recurrent/metastatic non-squamous NSCLC in patients with CrCl $\geq$ 45 mL/min	<ul style="list-style-type: none"> <li>After prior chemotherapy: 500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle (as a single agent).</li> </ul>	Until Disease Progression or Unacceptable Toxicity.
Mesothelioma treatment, in combination with cisplatin, in patients with CrCl $\geq$ 45 mL/min	<ul style="list-style-type: none"> <li>500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle</li> </ul>	Until Disease Progression or Unacceptable Toxicity. *American Society of Clinical Oncology guidelines for pleural mesothelioma recommend a duration of 4 to 6 cycles for pemetrexed-based chemotherapy; for patients with stable or responding disease, a break from chemotherapy is recommended at that point.
<b>Available Dosage Forms &amp; Strengths</b>		
<b>Pemfexy inj.</b>	<ul style="list-style-type: none"> <li>Injection: 500 mg/20 mL (25mg/mL) multi-dose vial</li> </ul>	
<b>Pemetrexed inj. (generic)</b>	<ul style="list-style-type: none"> <li>100 mg/4 mL (4 mL); 500 mg/20 mL (20 mL); 1 g/40 mL (40 mL) [Preservative Free]</li> </ul>	
<b>Pemetrexed disodium inj. (generic)</b>	<ul style="list-style-type: none"> <li>100 mg/4 mL (4 mL); 500 mg/20 mL (20 mL)</li> </ul>	
<b>Pemetrexed disodium inj. (generic)</b>	<ul style="list-style-type: none"> <li>100 mg/4 mL (4 mL); 500 mg/20 mL (20 mL); 1 g/40 mL (40 mL) [Preservative Free]</li> </ul>	
<b>Pemrydi RTU inj.</b>	<ul style="list-style-type: none"> <li>100 mg/10 mL (10 mL); 500 mg/50 mL (50 mL)</li> </ul>	
<b>Alimta inj. (Brand + generic)</b>	<ul style="list-style-type: none"> <li>Brand: 100 mg (1 ea) [Preservative Free]</li> <li>Generic: 100 mg (1 ea); 500 mg (1 ea); 750 mg (1 ea); 1000 mg (1 ea) [Preservative Free]</li> </ul>	
<b>Axtle inj. (Brand + generic)</b>	<ul style="list-style-type: none"> <li>Brand: 100 mg (1 ea); 500 mg (1 ea)</li> <li>Generic: 100 mg (1 ea); 500 mg (1 ea)</li> </ul>	
<b>Exceptions</b>		
<ul style="list-style-type: none"> <li>There is no recommended dose for patients whose creatinine clearance is less than 45 mL/min.</li> <li>Use in hemodialysis and peritoneal dialysis should be avoided.</li> <li>Recommended dosage modifications for adverse reactions:</li> </ul>		

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

Adverse reaction	Pemetrexed dosage modification for next cycle
<b>Hematologic toxicity</b>	
ANC <500/mm <sup>3</sup> <b>and</b> platelets ≥50,000/mm <sup>3</sup>	Delay the next cycle until ANC ≥1,500/mm <sup>3</sup> and platelets ≥100,000/mm <sup>3</sup> ; upon recovery, reduce pemetrexed dose to 75% of previous dose <sup>a</sup> .
Platelets <50,000/mm <sup>3</sup> <b>without</b> bleeding	Delay the next cycle until platelets ≥100,000/mm <sup>3</sup> ; upon recovery, reduce pemetrexed dose to 75% of previous dose <sup>a</sup> .
Platelets <50,000/mm <sup>3</sup> <b>with</b> bleeding	Delay the next cycle until platelets ≥100,000/mm <sup>3</sup> ; upon recovery, reduce pemetrexed dose to 50% of previous dose <sup>a</sup> .
Recurrent grade 3 or 4 myelosuppression after 2 dose reductions	Discontinue pemetrexed.
<b>Nonhematologic toxicity</b>	
Dermatologic toxicity: Severe or life-threatening bullous, blistering, or exfoliating skin toxicity	Permanently discontinue pemetrexed.
GI toxicity: Diarrhea, grade 3 or 4 <b>or</b> any diarrhea requiring hospitalization	Delay the next cycle until recovery to ≤ grade 2; upon recovery, reduce pemetrexed dose to 75% of previous dose.
GI toxicity: Mucositis, grade 3 or 4	Delay the next cycle until recovery to ≤ grade 2; upon recovery, reduce pemetrexed dose to 50% of previous dose.
Neurotoxicity, grade 3 or 4	Permanently discontinue pemetrexed.

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta®, Axtle®, Pemfexy®, Pemrydi®)	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

Pulmonary toxicity: Interstitial pneumonitis	Withhold pemetrexed for acute onset of new or progressive unexplained pulmonary symptoms (eg, dyspnea, cough, fever) and evaluate; if interstitial pneumonitis is confirmed, permanently discontinue pemetrexed.
Radiation recall (signs/symptoms)	Permanently discontinue pemetrexed.
Other toxicity, grade 3 or 4 toxicity	Delay the next cycle until recovery to ≤ grade 2; upon recovery, reduce pemetrexed dose to 75% of previous dose.
Recurrent grade 3 or 4 nonhematologic toxicity after 2 dose reductions	Permanently discontinue pemetrexed.

<sup>a</sup> If ANC <500/mm<sup>3</sup> or platelets <50,000/mm<sup>3</sup> in previous cycles, permanently reduce pemetrexed dose.

### Reference Information

1. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). *J Clin Oncol.* 2013; 31(24):3004-3011
2. Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. *Lung Cancer.* 2009; 64(2):211-218.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2024. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. *Clin Lung Cancer.* 2005; 7(1):40-46.
7. Kenmotsu H, Yamamoto N, Yamanaka T, et al. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.

## Utilization Management and Clinical Medical Policy

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pemfexy <sup>®</sup> , Pemrydi <sup>®</sup> )	MP-RX-FP-05-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	11/30/2023	03/24/2026
			Last Review Date: 03/24/2026	Frequently Revision: Annual

*J Clin Oncol.* 2020;38(19):2187- 2196. doi:10.1200/JCO.19.02674

8. Kreuter M, Vansteenkiste J, Fischer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol.* 2013;24(4):986-992. doi:10.1093/annonc/mds578
9. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
10. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed April 4, 2025.
  - a. Central Nervous System Cancers. V4.2024. Revised February 10, 2025.
  - b. Cervical Cancer. V3.2025. Revised January 21, 2025.
  - c. Head and Neck Cancers. V2.2025. Revised January 17, 2025.
  - d. Mesothelioma: Peritoneal. V2.2025. Revised January 14, 2025.
  - e. Non-Small Cell Lung Cancer. V3.2025. Revised January 14, 2025.
  - f. Ovarian Cancer, including fallopian tube cancer and primary peritoneal cancer. V1.2025. Revised March 5, 2025.
  - g. Thymomas and Thymic Carcinomas. V1.2025. Revised October 30, 2024
  - h. Vaginal Cancer. V5.2025. Revised February 28, 2025
11. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. *J Clin Oncol.* 2013; 31(34):4349-4357
12. Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. *Cancer.* 2012; 118(15):3743-3748.
13. Zhang L, Ou W, Liu Q, Li N, Liu L, Wang S. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. *Thorac Cancer.* 2014;5(1):50-56. doi:10.1111/1759-7714.12058. Available at: <https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.12058>. Accessed January 11, 2021.
14. UpToDate, Inc. (2026). *Pemetrexed: Drug information*. UpToDate. Retrieved February 1, 2026, from [https://www.uptodate.com/contents/pemetrexed-drug-information?search=pemetrexed&source=panel\\_search\\_result&selectedTitle=1~44&usage\\_type=panel&tp\\_tab=drug\\_general&display\\_rank=1#F207168](https://www.uptodate.com/contents/pemetrexed-drug-information?search=pemetrexed&source=panel_search_result&selectedTitle=1~44&usage_type=panel&tp_tab=drug_general&display_rank=1#F207168)

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta®, Axtle®, Pemfexy®, Pemrydi®)	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
---	---	--	--	---

© CPT Only – American Medical Association

### Policy History

Revision Type	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Added Axtle to service description and Background Information. Updated mesothelioma criteria, update NSCLC criteria, and non-nasopharyngeal head and neck cancer, added vaginal cancer, update thymomas and thymic carcinomas. Coding Reviewed: Updated description for HCPCS J9292. Added ICD-10-CM C00.0-C06.9, C09.0-C10.9, C12-C14.8, C31.0- C32.9, C52, C76.0. Removed C78.00-C78.02, C78.2. Updated dosing table: added combination regimens, duration of therapy, and available dosage forms and dosage modifications. Updated references. Wording and formatting changes.	3/17/2026	3/24/2026
Annual Review	Add Axtle to criteria. Coding Reviewed: Added HCPCS NOC J9999 and C9399 for Axtle, add HCPCS J9292 effective 1/1/25. Add ICD-10-CM C33, C53.0-C53.9, C79.32, C83.390. Removed ICD-10-CM C38.0-C38.8 code range and add C38.4. Remove ICD-10-CM C61, C65.1-C65.9, C66.1-C68.0.	6/9/2025	6/19/2025
Annual Review	Add Pemrydi, Add induction therapy for Non-small cell lung cancer, cervical cancer, primary central nervous system lymphoma and NSCLC CNS metastases; Add combination use with Rybrevant and carboplatin for Non-small cell lung cancer, formatting. Coding Reviewed: Updated coding description for HCPCS J9314, J9322, J9323, J9294, J9296, J9297.	2/18/2025	3/6/2025

## Utilization Management and Clinical Medical Policy

<b>Policy Name:</b> Pemetrexed (Alimta <sup>®</sup> , Axtle <sup>®</sup> , Pefexy <sup>®</sup> , Pemrydi <sup>®</sup> )	<b>Policy Number:</b> MP-RX-FP-05-23	<b>Scope:</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	<b>Origination Date:</b> 11/30/2023 <b>Last Review Date:</b> 03/24/2026	<b>Effective Date:</b> 03/24/2026 <b>Frequently Revision:</b> Annual
--	---	--	--	---

Focus Review	Update statement for criteria for initial approval: Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met all approval criteria.	3/25/2024	5/9/2024
Policy Inception	Elevance Health’s Medical Policy adoption.	N/A	11/30/2023